We develop medicines to defeat diseases of aging

Roxiant is a preclinical stage biotech company developing first-in-class medicines to slow, halt, and reverse neurodegenerative diseases. Our drug candidates uniquely activate multifactorial repair mechanisms that counteract age-related cellular damage in human cells.

Our Science

Our Scientific Founder Professor Annibale Puca is a leading expert on longevity. For three decades he has been studying long living individuals. His discovery of a key longevity associated protein has paved the way for a new class of medicines.

Watch our scientific discovery explained in three minutes

Learn how we develop medicines based on the longevity associated protein LAV-BPIFB4 found in long living individuals.

The caretaker of human cells in long living individuals

In studies covering more than 5,000 people, Professor Puca was the first to discover the longevity associated protein LAV-BPIFB4 that works as the 'caretaker' of the human cells in long living individuals. 

Identifies and repairs age-related damages in human cells

As any good caretaker LAV-BPIFB4 looks out for and repairs age-related damages in the cells. Its proactive multifactorial repair keep damages from accumulating and causing permanent loss of function.

Our lead drug candidate RX-1 is a novel therapy for Huntington’s Disease

RX-1 is the first long-acting non-invasive therapy with a strong preclinical proof-of-concept in Huntington's Disease.

Validated and patented as therapy for severe neurodegenerative diseases

Our ambition is to develop RX-1 as a treatment for Huntington’s Diseases, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson’s Disease, and Alzheimer’s Disease.

Our Publications

Our scientists have extensively researched the therapeutic and mechanistic characteristics of LAV-BPIFB4 over last decades. Here are some recent publications:

Our Team

We are a team of leading scientists, drug development experts, and industry leaders from Denmark, Italy, England, and Germany. We work collaboratively from our business operations in Denmark and our research operations in Italy.


Andreas Christensen, MSc, MBA

Chief Executive Officer

Kasper Gubba Ørtenblad, MSc Bio

Chief Operating Officer

Bob Clay, MSc Pharm, MBA

Chief Regulatory Officer

Dr. Søren Salling, MD, MBA

Chief Medical Officer

Kishor Modha, BSc, PhD

CMC Projects Director

Jay Modha, BSc, PhD

CMC Technical Director

Board of Directors

Rasmus Just, MSc, PhD Pharm, MBA

Chairman of the Board

Prof Annibale Alessandro Puca, MD

Board Member, Scientific Chair

Prof Ferdinando Nicoletti, MD

Board Member, Clinical Chair

Strategic Advisors

Asst Prof Niels Henning Skotte, PhD

Chair, Scientific Advisory Board

Prof Alberto Auricchio, MD

Scientific Advisor

Dr. Elena Ciaglia, MD, PhD

Scientific Advisor

Klaus Berding, MEBA

Corporate Advisor

Alexander Peitersen, MSc, MBA

Corporate Advisor


"We are deeply committed to serving patients and relatives affected by severe age-related diseases by advancing our novel drug program. And we welcome investors with shared purpose to join us."

Andreas Christensen, Co-founder & CEO

Roxiant relies on financing from investors to accelerate our drug development program. We invite investors to contact our CEO Andreas Christensen (asc@roxiant.com) if you are interested in:

1. Receiving our investor presentation
2. Scheduling an introductory meeting
3. Signing-up for our investor newsletters

Partnering & Licensing

Roxiant’s novel therapeutic platform has demonstrated strong in vivo proof-of-concept in multiple diseases with complex pathologies. It may exert therapeutic effects in areas with significant unmet medical needs:

  • Cardiovascular diseases
  • Diabetic diseases
  • COVID-19

Supported by strong patent protection with late expiry, our out-licensed partnership program is aimed at accelerating the development of novel drug candidates for patients with unmet medical needs.

We invite potential drug development and licensing partners to contact our CEO Andreas Christensen (asc@roxiant.com).

Partnering & Licensing

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Cardiovascular diseases

Put your best foot forward

Risus sapien facicisis purus at molestie et, sed rhoncus diam. Corbi leo, pellentesque ante metus. Leo, odio vulputate at id nunc.